Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases

•The structures of active cathepsin A and the inactive precursor are very similar.•The only major difference is the absence of a 40 residue activation domain.•The termini of the active catalytic core are held together by a disulfide bond.•Compound 1 reacts with the catalytic Ser150, building a tetra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochemical and biophysical research communications 2014-03, Vol.445 (2), p.451-456
Hauptverfasser: Schreuder, Herman A., Liesum, Alexander, Kroll, Katja, Böhnisch, Britta, Buning, Christian, Ruf, Sven, Sadowski, Thorsten
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 456
container_issue 2
container_start_page 451
container_title Biochemical and biophysical research communications
container_volume 445
creator Schreuder, Herman A.
Liesum, Alexander
Kroll, Katja
Böhnisch, Britta
Buning, Christian
Ruf, Sven
Sadowski, Thorsten
description •The structures of active cathepsin A and the inactive precursor are very similar.•The only major difference is the absence of a 40 residue activation domain.•The termini of the active catalytic core are held together by a disulfide bond.•Compound 1 reacts with the catalytic Ser150, building a tetrahedral intermediate.•Compound 2 is cleaved by the enzyme and a fragment remained bound. The lysosomal serine carboxypeptidase cathepsin A is involved in the breakdown of peptide hormones like endothelin and bradykinin. Recent pharmacological studies with cathepsin A inhibitors in rodents showed a remarkable reduction in cardiac hypertrophy and atrial fibrillation, making cathepsin A a promising target for the treatment of heart failure. Here we describe the crystal structures of activated cathepsin A without inhibitor and with two compounds that mimic the tetrahedral intermediate and the reaction product, respectively. The structure of activated cathepsin A turned out to be very similar to the structure of the inactive precursor. The only difference was the removal of a 40 residue activation domain, partially due to proteolytic removal of the activation peptide, and partially by an order–disorder transition of the peptides flanking the removed activation peptide. The termini of the catalytic core are held together by the Cys253–Cys303 disulfide bond, just before and after the activation domain. One of the compounds we soaked in our crystals reacted covalently with the catalytic Ser150 and formed a tetrahedral intermediate. The other compound got cleaved by the enzyme and a fragment, resembling one of the natural reaction products, was found in the active site. These studies establish cathepsin A as a classical serine proteinase with a well-defined oxyanion hole. The carboxylate group of the cleavage product is bound by a hydrogen-bonding network involving one aspartate and two glutamate side chains. This network can only form if at least half of the carboxylate groups involved are protonated, which explains the acidic pH optimum of the enzyme.
doi_str_mv 10.1016/j.bbrc.2014.02.014
format Article
fullrecord <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22416308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X14002666</els_id><sourcerecordid>1508414650</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-ed6153abebf7f5f95162377d01e9e6281cae2b165cd5f7d4df3bd39fb44b1b23</originalsourceid><addsrcrecordid>eNp9kE1v1DAURS0EokPhD7BAltiwIOl7jpOZSGyqUQtIldh00Q2y_PFMPcrEg-2M1H9PohSWrO7inXv1dBh7j1AjYHd1qI1JthaAsgZRz_GCbRB6qASCfMk2ANBVoseHC_Ym5wMAouz61-xCyLaBHuWG_dynp1z0wHNJky1TIh49t7o80imHkV9_5pqP8UwDLzr9osJ9THy-8pJIlyONZS0kF-JZZzsNOnEXMulM-S175fWQ6d1zXrL725v7_bfq7sfX7_vru8o2O1kqch22jTZk_Na3vm-xE8126wCpp07s0GoSBrvWutZvnXS-Ma7pvZHSoBHNJfu4zsZcgso2FLKPNo4j2aKEkNg1sJupTyt1SvH3RLmoY8iWhkGPFKessIWdnAW1MKNiRW2KOSfy6pTCUacnhaAW9-qgFvdqca9AqDnm0ofn_ckcyf2r_JU9A19WgGYV50BpeZVGSy6k5VMXw__2_wDys5W2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1508414650</pqid></control><display><type>article</type><title>Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Schreuder, Herman A. ; Liesum, Alexander ; Kroll, Katja ; Böhnisch, Britta ; Buning, Christian ; Ruf, Sven ; Sadowski, Thorsten</creator><creatorcontrib>Schreuder, Herman A. ; Liesum, Alexander ; Kroll, Katja ; Böhnisch, Britta ; Buning, Christian ; Ruf, Sven ; Sadowski, Thorsten</creatorcontrib><description>•The structures of active cathepsin A and the inactive precursor are very similar.•The only major difference is the absence of a 40 residue activation domain.•The termini of the active catalytic core are held together by a disulfide bond.•Compound 1 reacts with the catalytic Ser150, building a tetrahedral intermediate.•Compound 2 is cleaved by the enzyme and a fragment remained bound. The lysosomal serine carboxypeptidase cathepsin A is involved in the breakdown of peptide hormones like endothelin and bradykinin. Recent pharmacological studies with cathepsin A inhibitors in rodents showed a remarkable reduction in cardiac hypertrophy and atrial fibrillation, making cathepsin A a promising target for the treatment of heart failure. Here we describe the crystal structures of activated cathepsin A without inhibitor and with two compounds that mimic the tetrahedral intermediate and the reaction product, respectively. The structure of activated cathepsin A turned out to be very similar to the structure of the inactive precursor. The only difference was the removal of a 40 residue activation domain, partially due to proteolytic removal of the activation peptide, and partially by an order–disorder transition of the peptides flanking the removed activation peptide. The termini of the catalytic core are held together by the Cys253–Cys303 disulfide bond, just before and after the activation domain. One of the compounds we soaked in our crystals reacted covalently with the catalytic Ser150 and formed a tetrahedral intermediate. The other compound got cleaved by the enzyme and a fragment, resembling one of the natural reaction products, was found in the active site. These studies establish cathepsin A as a classical serine proteinase with a well-defined oxyanion hole. The carboxylate group of the cleavage product is bound by a hydrogen-bonding network involving one aspartate and two glutamate side chains. This network can only form if at least half of the carboxylate groups involved are protonated, which explains the acidic pH optimum of the enzyme.</description><identifier>ISSN: 0006-291X</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2014.02.014</identifier><identifier>PMID: 24530914</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; BRADYKININ ; CARBOXYPEPTIDASES ; CARDIOVASCULAR DISEASES ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - enzymology ; Cathepsin A - antagonists &amp; inhibitors ; Cathepsin A - chemistry ; Cathepsin A - isolation &amp; purification ; Cathepsin A - metabolism ; CATHEPSINS ; CHEMICAL BONDS ; COVALENCE ; Covalent inhibitor ; CRYSTAL STRUCTURE ; Crystallography, X-Ray ; DISULFIDES ; Drug Discovery ; DRUGS ; Endothelin ; HEART FAILURE ; Humans ; HYPERTROPHY ; Ligands ; Models, Molecular ; Molecular Targeted Therapy ; PEPTIDE HORMONES ; PH VALUE ; Protein Binding ; Protein Conformation ; Recombinant Proteins - chemistry ; Recombinant Proteins - isolation &amp; purification ; Recombinant Proteins - metabolism ; SERINE ; Serine carboxypeptidase ; Tetrahedral intermediate</subject><ispartof>Biochemical and biophysical research communications, 2014-03, Vol.445 (2), p.451-456</ispartof><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-ed6153abebf7f5f95162377d01e9e6281cae2b165cd5f7d4df3bd39fb44b1b23</citedby><cites>FETCH-LOGICAL-c384t-ed6153abebf7f5f95162377d01e9e6281cae2b165cd5f7d4df3bd39fb44b1b23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006291X14002666$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24530914$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22416308$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Schreuder, Herman A.</creatorcontrib><creatorcontrib>Liesum, Alexander</creatorcontrib><creatorcontrib>Kroll, Katja</creatorcontrib><creatorcontrib>Böhnisch, Britta</creatorcontrib><creatorcontrib>Buning, Christian</creatorcontrib><creatorcontrib>Ruf, Sven</creatorcontrib><creatorcontrib>Sadowski, Thorsten</creatorcontrib><title>Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>•The structures of active cathepsin A and the inactive precursor are very similar.•The only major difference is the absence of a 40 residue activation domain.•The termini of the active catalytic core are held together by a disulfide bond.•Compound 1 reacts with the catalytic Ser150, building a tetrahedral intermediate.•Compound 2 is cleaved by the enzyme and a fragment remained bound. The lysosomal serine carboxypeptidase cathepsin A is involved in the breakdown of peptide hormones like endothelin and bradykinin. Recent pharmacological studies with cathepsin A inhibitors in rodents showed a remarkable reduction in cardiac hypertrophy and atrial fibrillation, making cathepsin A a promising target for the treatment of heart failure. Here we describe the crystal structures of activated cathepsin A without inhibitor and with two compounds that mimic the tetrahedral intermediate and the reaction product, respectively. The structure of activated cathepsin A turned out to be very similar to the structure of the inactive precursor. The only difference was the removal of a 40 residue activation domain, partially due to proteolytic removal of the activation peptide, and partially by an order–disorder transition of the peptides flanking the removed activation peptide. The termini of the catalytic core are held together by the Cys253–Cys303 disulfide bond, just before and after the activation domain. One of the compounds we soaked in our crystals reacted covalently with the catalytic Ser150 and formed a tetrahedral intermediate. The other compound got cleaved by the enzyme and a fragment, resembling one of the natural reaction products, was found in the active site. These studies establish cathepsin A as a classical serine proteinase with a well-defined oxyanion hole. The carboxylate group of the cleavage product is bound by a hydrogen-bonding network involving one aspartate and two glutamate side chains. This network can only form if at least half of the carboxylate groups involved are protonated, which explains the acidic pH optimum of the enzyme.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>BRADYKININ</subject><subject>CARBOXYPEPTIDASES</subject><subject>CARDIOVASCULAR DISEASES</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - enzymology</subject><subject>Cathepsin A - antagonists &amp; inhibitors</subject><subject>Cathepsin A - chemistry</subject><subject>Cathepsin A - isolation &amp; purification</subject><subject>Cathepsin A - metabolism</subject><subject>CATHEPSINS</subject><subject>CHEMICAL BONDS</subject><subject>COVALENCE</subject><subject>Covalent inhibitor</subject><subject>CRYSTAL STRUCTURE</subject><subject>Crystallography, X-Ray</subject><subject>DISULFIDES</subject><subject>Drug Discovery</subject><subject>DRUGS</subject><subject>Endothelin</subject><subject>HEART FAILURE</subject><subject>Humans</subject><subject>HYPERTROPHY</subject><subject>Ligands</subject><subject>Models, Molecular</subject><subject>Molecular Targeted Therapy</subject><subject>PEPTIDE HORMONES</subject><subject>PH VALUE</subject><subject>Protein Binding</subject><subject>Protein Conformation</subject><subject>Recombinant Proteins - chemistry</subject><subject>Recombinant Proteins - isolation &amp; purification</subject><subject>Recombinant Proteins - metabolism</subject><subject>SERINE</subject><subject>Serine carboxypeptidase</subject><subject>Tetrahedral intermediate</subject><issn>0006-291X</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAURS0EokPhD7BAltiwIOl7jpOZSGyqUQtIldh00Q2y_PFMPcrEg-2M1H9PohSWrO7inXv1dBh7j1AjYHd1qI1JthaAsgZRz_GCbRB6qASCfMk2ANBVoseHC_Ym5wMAouz61-xCyLaBHuWG_dynp1z0wHNJky1TIh49t7o80imHkV9_5pqP8UwDLzr9osJ9THy-8pJIlyONZS0kF-JZZzsNOnEXMulM-S175fWQ6d1zXrL725v7_bfq7sfX7_vru8o2O1kqch22jTZk_Na3vm-xE8126wCpp07s0GoSBrvWutZvnXS-Ma7pvZHSoBHNJfu4zsZcgso2FLKPNo4j2aKEkNg1sJupTyt1SvH3RLmoY8iWhkGPFKessIWdnAW1MKNiRW2KOSfy6pTCUacnhaAW9-qgFvdqca9AqDnm0ofn_ckcyf2r_JU9A19WgGYV50BpeZVGSy6k5VMXw__2_wDys5W2</recordid><startdate>20140307</startdate><enddate>20140307</enddate><creator>Schreuder, Herman A.</creator><creator>Liesum, Alexander</creator><creator>Kroll, Katja</creator><creator>Böhnisch, Britta</creator><creator>Buning, Christian</creator><creator>Ruf, Sven</creator><creator>Sadowski, Thorsten</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20140307</creationdate><title>Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases</title><author>Schreuder, Herman A. ; Liesum, Alexander ; Kroll, Katja ; Böhnisch, Britta ; Buning, Christian ; Ruf, Sven ; Sadowski, Thorsten</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-ed6153abebf7f5f95162377d01e9e6281cae2b165cd5f7d4df3bd39fb44b1b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>BRADYKININ</topic><topic>CARBOXYPEPTIDASES</topic><topic>CARDIOVASCULAR DISEASES</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - enzymology</topic><topic>Cathepsin A - antagonists &amp; inhibitors</topic><topic>Cathepsin A - chemistry</topic><topic>Cathepsin A - isolation &amp; purification</topic><topic>Cathepsin A - metabolism</topic><topic>CATHEPSINS</topic><topic>CHEMICAL BONDS</topic><topic>COVALENCE</topic><topic>Covalent inhibitor</topic><topic>CRYSTAL STRUCTURE</topic><topic>Crystallography, X-Ray</topic><topic>DISULFIDES</topic><topic>Drug Discovery</topic><topic>DRUGS</topic><topic>Endothelin</topic><topic>HEART FAILURE</topic><topic>Humans</topic><topic>HYPERTROPHY</topic><topic>Ligands</topic><topic>Models, Molecular</topic><topic>Molecular Targeted Therapy</topic><topic>PEPTIDE HORMONES</topic><topic>PH VALUE</topic><topic>Protein Binding</topic><topic>Protein Conformation</topic><topic>Recombinant Proteins - chemistry</topic><topic>Recombinant Proteins - isolation &amp; purification</topic><topic>Recombinant Proteins - metabolism</topic><topic>SERINE</topic><topic>Serine carboxypeptidase</topic><topic>Tetrahedral intermediate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schreuder, Herman A.</creatorcontrib><creatorcontrib>Liesum, Alexander</creatorcontrib><creatorcontrib>Kroll, Katja</creatorcontrib><creatorcontrib>Böhnisch, Britta</creatorcontrib><creatorcontrib>Buning, Christian</creatorcontrib><creatorcontrib>Ruf, Sven</creatorcontrib><creatorcontrib>Sadowski, Thorsten</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schreuder, Herman A.</au><au>Liesum, Alexander</au><au>Kroll, Katja</au><au>Böhnisch, Britta</au><au>Buning, Christian</au><au>Ruf, Sven</au><au>Sadowski, Thorsten</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2014-03-07</date><risdate>2014</risdate><volume>445</volume><issue>2</issue><spage>451</spage><epage>456</epage><pages>451-456</pages><issn>0006-291X</issn><eissn>1090-2104</eissn><abstract>•The structures of active cathepsin A and the inactive precursor are very similar.•The only major difference is the absence of a 40 residue activation domain.•The termini of the active catalytic core are held together by a disulfide bond.•Compound 1 reacts with the catalytic Ser150, building a tetrahedral intermediate.•Compound 2 is cleaved by the enzyme and a fragment remained bound. The lysosomal serine carboxypeptidase cathepsin A is involved in the breakdown of peptide hormones like endothelin and bradykinin. Recent pharmacological studies with cathepsin A inhibitors in rodents showed a remarkable reduction in cardiac hypertrophy and atrial fibrillation, making cathepsin A a promising target for the treatment of heart failure. Here we describe the crystal structures of activated cathepsin A without inhibitor and with two compounds that mimic the tetrahedral intermediate and the reaction product, respectively. The structure of activated cathepsin A turned out to be very similar to the structure of the inactive precursor. The only difference was the removal of a 40 residue activation domain, partially due to proteolytic removal of the activation peptide, and partially by an order–disorder transition of the peptides flanking the removed activation peptide. The termini of the catalytic core are held together by the Cys253–Cys303 disulfide bond, just before and after the activation domain. One of the compounds we soaked in our crystals reacted covalently with the catalytic Ser150 and formed a tetrahedral intermediate. The other compound got cleaved by the enzyme and a fragment, resembling one of the natural reaction products, was found in the active site. These studies establish cathepsin A as a classical serine proteinase with a well-defined oxyanion hole. The carboxylate group of the cleavage product is bound by a hydrogen-bonding network involving one aspartate and two glutamate side chains. This network can only form if at least half of the carboxylate groups involved are protonated, which explains the acidic pH optimum of the enzyme.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24530914</pmid><doi>10.1016/j.bbrc.2014.02.014</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-291X
ispartof Biochemical and biophysical research communications, 2014-03, Vol.445 (2), p.451-456
issn 0006-291X
1090-2104
language eng
recordid cdi_osti_scitechconnect_22416308
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects 60 APPLIED LIFE SCIENCES
BRADYKININ
CARBOXYPEPTIDASES
CARDIOVASCULAR DISEASES
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - enzymology
Cathepsin A - antagonists & inhibitors
Cathepsin A - chemistry
Cathepsin A - isolation & purification
Cathepsin A - metabolism
CATHEPSINS
CHEMICAL BONDS
COVALENCE
Covalent inhibitor
CRYSTAL STRUCTURE
Crystallography, X-Ray
DISULFIDES
Drug Discovery
DRUGS
Endothelin
HEART FAILURE
Humans
HYPERTROPHY
Ligands
Models, Molecular
Molecular Targeted Therapy
PEPTIDE HORMONES
PH VALUE
Protein Binding
Protein Conformation
Recombinant Proteins - chemistry
Recombinant Proteins - isolation & purification
Recombinant Proteins - metabolism
SERINE
Serine carboxypeptidase
Tetrahedral intermediate
title Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T18%3A58%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Crystal%20structure%20of%20cathepsin%20A,%20a%20novel%20target%20for%20the%20treatment%20of%20cardiovascular%20diseases&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Schreuder,%20Herman%20A.&rft.date=2014-03-07&rft.volume=445&rft.issue=2&rft.spage=451&rft.epage=456&rft.pages=451-456&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2014.02.014&rft_dat=%3Cproquest_osti_%3E1508414650%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1508414650&rft_id=info:pmid/24530914&rft_els_id=S0006291X14002666&rfr_iscdi=true